Iveric Bio Announces Presentation of Post-Hoc Analysis at Macula Society from GATHER1 Clinical Trial…
IVERIC bio, Inc. announced a post-hoc analysis from the Zimura (avacincaptad pegol) GATHER1 clinical trial which explored enhanced Optical Coherence…